adenocarcinoma (gastric cancer, colorectal cancer, or bile duct cancer)
Conditions
Interventions
None listed
Sponsors
University of Miyazaki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adenocarcinoma group 1.Patients aged equal to or greater than 20 years-old. 2.Patients who have the schedule for surgical treatment, endoscopic submucosal dissection, or endoscopic mucosal resection. 3. Patients diagnosed adenocarcinoma by histopathology. 4. Patients who had a detailed briefing of the trial prior to the enrollment and voluntarily signed a consent form. Disease control group 1.Patients aged equal to or greater than 20 years-old. 2. Patients who were clinicaly diagnosed gastrointestinal inflammation by gastoroscopy or colonoscopy within 3 months or who were clinicaly diagnosed cholelithiasis or colonic diverticulitis by CT within 6 months. 3.Patients who had a detailed briefing of the trial prior to the enrollment and voluntarily signed a consent form. Healthy controls 1. Those who are equal to or greater than 20 years-old at the time of obtaining informed consent. 2. Those who have no abnormal findings in chest X-ray, blood glucose levels, serum lipids, serum liver function, serum renal function, and urinalysis within one year of obtaining informed consent. 3. Those who do not receive any regular prescriptions. 4. Those who had a detailed briefing of the trial prior to the enrollment and voluntarily signed a consent form
Exclusion criteria
Exclusion criteria: Adenocarcinoma group 1. Patients who do not have the schedule for surgical treatment, endoscopic submucosal dissection, or endoscopic mucosal resection. 2. Patients who received chemotherapy or endoscpic treatment. 3. Patients who have proteinuria, positive urine sugar or urine occult blood in urinalysis. 4. Patients who have renal dysfunction (Serum levels of creatinine > 2.0 mg/dl). 5. Patients who have alcohol or drug dependence or who are suspected to have alcohol or drug dependence. 6. Patients who is pregnant or who is suspected to be pregnant. 7. Patients who was enrolled another clinical trial and was prescribed a study drug within one month. 8. Patients whose attending physicians consider to be inappropriate for this study. Disease control group 1. Patients who were not clinicaly diagnosed gastrointestinal inflammation by gastoroscopy or colonoscopy within 3 months or who were not clinicaly diagnosed cholelithiasis or colonic diverticulitis by CT within 6 months. 2. Patients who have proteinuria, positive urine sugar or urine occult blood in urinalysis. 3. Patients who have renal dysfunction (Serum levels of creatinine > 2.0 mg/dl). 4. Patients who have alcohol or drug dependence or who are suspected to have alcohol or drug dependence. 5-7. Same criterias as Adenocarcinoma group (6-8). Healthy controls 1. Those who have not received a medical check within one year. 2. Those who have abnormal findings in chest X-ray, blood test or urine test within one year of obtaining informed consent. 3. Those who have current malignant neoplasm other than lung squamous cell carcinoma, or past history of malignant neoplasm within 5 years. 4. Those who have alcohol or drug dependence or who are suspected to have alcohol or drug dependence. 5-7. Same criterias as Adenocarcinoma group (6-8).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of diagnostic accuracy of urinary protein fragments and carcinoembryonic antigen (CEA) for adenocarcinoma (gastric cancer, colorectal cancer, or bile duct cancer) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Comparison of diagnostic accuracy of urinary protein fragment and CA19-9 for adenocarcinoma 2)Diagnostic accuracy of combination marker (urinary protein fragments, CEA and CA19-9) 3)Comparison of diagnostic accuracy of urinary protein fragments and blood tumor marker(CEA or CA19-9) for gastric cancer 4)Comparison of diagnostic accuracy of urinary protein fragments and blood tumor marker(CEA or CA19-9) for colorectal cancer 5)Comparison of diagnostic accuracy of urinary protein fragments and blood tumor marker(CEA or CA19-9) for bile duct cancer | — |
Countries
Japan
Contacts
Public ContactHironobu Tsubouchi
University of Miyazaki Neurology, Respirology, Endocrinology and Metabolism, Internal Medicine, Faculty of Medicine
Outcome results
None listed